Bexion Pharmaceuticals

Formulation of a synthetically produced, human lysosomal protein for the potential treatment of glioblastoma.

placeCovington, Kentucky, United States calendar_todayFounded 2006 groups48 employees language bexionpharma.com

Registered entities

Innovation

5 patent families (1 granted) — focus: Human necessities; filing pace slowing. Cited 325 times.

YearFilings
20181
20192
20201
20211
20223
20234
20242
20251

Investor mix

5 investors on record.

Investor typeCountShare
Venture capital360%
Other / undisclosed240%
Coming soon